Dr Matthew Campbell graduated from University College Dublin (UCD) in 2006 with a PhD in Biochemistry followed by Post-doctoral research in Trinity College Dublin (TCD) in Human Molecular Genetics (2006-2012). He has published extensively on the use of RNA interference (RNAi) to modulate levels of distinct tight junction proteins at the blood-brain barrier/inner blood retina barrier (BBB/iBRB) in vivo. Additionally, he has published numerous articles focused on understanding the molecular pathology of diseases such as age-related macular degeneration (AMD), Alzheimer's disease, Schizophrenia, traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE). He leads the Neurovascular Genetics Research group based in the Smurfit Institute of Genetics at TCD where he is also a lecturer in Human Genetics.
In 2013, he was awarded Science Foundation Ireland's (SFI) most prestigious prize for young researchers, the President of Ireland Young Researcher Award (PIYRA) in relation to his BBB based research. In the same year, he was awarded the Genentech/ARVO research fellowship for his ophthalmology focused work related to AMD. This work led to numerous papers including Nature Medicine (2012, 2014) and Science Translational Medicine (2014) describing the therapeutic potential for IL-18 and its use in treating patients with wet AMD.
For more information see: www.bbb2014dublin.com.